Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Neuropsychological, Social, Emotional and Behavioral Outcomes in Children with Cancer
Multiple Cancer Types
Miscellaneous,
Neuro-Oncology,
Pediatrics
N/A
Friedman, Debra
NCT00772200
COGALTE07C1
Key Adverse Events after Childhood Cancer
Multiple Cancer Types
Miscellaneous,
Pediatric Leukemia,
Pediatrics
N/A
Friedman, Debra
NCT00082745
COGALTE03N1
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Miscellaneous
Miscellaneous
Miscellaneous
N/A
Friedman, Debra
COGAPEC14B1
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
Multiple Cancer Types
This randomized phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as doxorubicin, vinblastine, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The addition of nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer or extend the time without disease symptoms coming back.
Pediatric Lymphoma,
Pediatrics
III
Friedman, Debra
NCT03907488
COGPEDS1826
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667 / KEYNOTE-667)
Multiple Cancer Types
This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.
Pediatric Lymphoma,
Pediatrics
II
Friedman, Debra
NCT03407144
VICCPED1994
Late Effects after Treatment in Patients with Previously Diagnosed High-Risk Neuroblastoma
Multiple Cancer Types
This research trial studies late effects after treatment in patients with previously diagnosed high-risk neuroblastoma. Studying late effects after treatment may help to decide which treatments for high-risk neuroblastoma are better tolerated with less side effects over time.
Neuroblastoma (Pediatrics),
Pediatrics
N/A
Friedman, Debra
NCT03057626
COGALTE15N2
Studying Health Outcomes after Treatment in Patients with Retinoblastoma, RIVERBOAT Study
Multiple Cancer Types
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma.
Pediatrics,
Retinoblastoma (Pediatrics)
N/A
Friedman, Debra
NCT03932786
VICCPED1878
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome
Multiple Cancer Types
This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Response-based chemotherapy separates patients into different risk groups and treats them according to how they respond to the first course of treatment (Induction I). Response-based treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome while reducing the side effects.
Myelodysplastic Syndrome,
Pediatric Leukemia
III
Friedman, Debra
NCT02521493
COGAAML1531
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Pediatric Leukemia
Pediatric Leukemia
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
Pediatric Leukemia
II
Friedman, Debra
NCT02723994
VICCPED16131
Umbrella Long-Term Follow-Up Protocol
Pediatrics
Pediatrics
Pediatrics
N/A
Friedman, Debra
NCT00736749
COGALTE05N1